Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Cellectis SA (0WA2) Share Price & Analysis

0 Followers

0WA2 Stock Chart & Stats

€1.24-€0.00(-0.08%)
At close: 4:30 PM GMT
€1€2€3Aug 17Sep 1Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
EUR 1.24 - EUR 1.32
52-Week Range
EUR 0.90 - EUR 4.75
Previous Close
EUR 1.24
Volume
N/A
Average Volume (3M)
2,649
Market Cap
EUR 97.71M
Enterprise Value
EUR 205.35M
Total Cash (Recent Filing)
EUR 166.85M
Total Debt (Recent Filing)
EUR 84.57M
Price to Earnings (P/E)
―
Beta
0.34
Next Earnings
Mar 04, 2027 (Est.)
EPS Estimate
-0.17
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Allogeneic Cell Therapy Platform

Cellectis is developing an allogeneic, gene-edited T-cell platform designed for off-the-shelf cancer therapies. If clinical development succeeds, this approach could support repeatable manufacturing and broader patient access, creating strategic value beyond any single candidate.

Strong Gross Margin

A gross margin of approximately 75% indicates that Cellectis’s underlying revenue streams can retain substantial value after direct costs. Although operating expenses currently overwhelm gross profit, this margin profile could provide operating leverage if partnerships, milestones, or services scale.

Demonstrated Cash Generation Potential

Positive operating and free cash flow in 2024 demonstrates that Cellectis has previously been able to convert activities into cash, even though that performance was not sustained. This provides evidence of potential flexibility if collaboration receipts or operating conditions improve.

Bears Say

Declining Revenue And Deep Losses

The recent revenue contraction is occurring alongside very large operating and net losses, showing that the current revenue base does not cover the company’s cost structure. Continued losses could delay break-even and keep results dependent on future development or partnership proceeds.

Persistent Cash Burn

Substantial negative operating and free cash flow means Cellectis is consuming cash while advancing its clinical-stage programs. If this pattern persists, the company may need additional funding, which can reduce financial flexibility and make development progress more dependent on external capital.

Higher Leverage And Weaker Equity Cushion

Higher debt relative to a materially reduced equity base leaves Cellectis with a weaker balance-sheet cushion while returns remain sharply negative. This combination can constrain capital allocation and increase pressure to secure funding before clinical investment needs are fully met.

Cellectis SA News

0WA2 FAQ

What was Cellectis SA’s price range in the past 12 months?
Cellectis SA lowest share price was €0.90 and its highest was €4.75 in the past 12 months.
What is Cellectis SA’s market cap?
Cellectis SA’s market cap is €97.71M.
When is Cellectis SA’s upcoming earnings report date?
Cellectis SA’s next earnings report is estimated for Mar 04, 2027 (not yet confirmed), which is in 111 days.
How were Cellectis SA’s earnings last quarter?
Cellectis SA released its earnings results on Nov 12, 2026. The company reported -€0.551 earnings per share for the quarter, missing the consensus estimate of -€0.156 by -€0.395.
Is Cellectis SA overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Cellectis SA pay dividends?
Cellectis SA does not currently pay dividends.
What is Cellectis SA’s EPS estimate?
Cellectis SA’s EPS estimate is -0.17.
How many shares outstanding does Cellectis SA have?
Cellectis SA has 72,325,455 shares outstanding.
What happened to Cellectis SA’s price movement after its last earnings report?
Cellectis SA reported an EPS of -€0.551 in its last earnings report, missing expectations of -€0.156. Following the earnings report the stock price went same ―.
Which hedge fund is a major shareholder of Cellectis SA?
Currently, no hedge funds are holding shares in GB:0WA2
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology